

Prescription Start Form

Phone: 1-866- AKCEATX (1-866-252-3289) **Fax:** 1-866-AKCEAFX (1-866-252-3239)

Email: AkceaConnect@akceatx.com



All fields mandatory

1. PATIENT INFORMATION									
First Name		Middle Initial	Last Name			Date of Birth (mm/dd/yyyy)		Gender <input type="checkbox"/> M <input type="checkbox"/> F	
Home Address						City			
State			ZIP Code		Last four digits of SS#		XXX-XX-XXXX		
Shipping Address (If Not Home Address)									
Care of (If different than Pt.)			City			State		ZIP Code	
Home Phone # <input type="checkbox"/> OK to leave Message			Mobile # <input type="checkbox"/> OK to Text		Best Time to Call		Preferred Language (If other than English)		
Email Address				Pt. Representative/ Caregiver Name					
Relationship		Pt. Rep Phone #			Pt. Rep Email Address				
2. INSURANCE INFORMATION: (Please include front and back copies of insurance cards) If no insurance please check here <input type="checkbox"/>									
Primary Insurance			Policy Holder			Date of Birth (mm/dd/yyyy)			
Policy #			Group #			Phone #			
Secondary Insurance			Policy Holder			Date of Birth (mm/dd/yyyy)			
Policy #			Group #			Phone #			
Prescription Insurance			Policy Holder			Date of Birth (mm/dd/yyyy)			
Member ID #		Group #		Rx Bin #		PCN #		Phone #	
3. HEALTHCARE PROVIDER (HCP) INFORMATION									
HCP First Name		HCP Last Name			Office/Clinic/ Facility Name				
National Provider ID (NPI) #			Tax ID #		State License #		Phone #		
Address									
City					State		ZIP Code		
Office Contact			Contact Phone #			Office Fax #			
Email Address					Preferred Method of Contact				
4. PRESCRIPTION INFORMATION: TEGSEDI® 284 MG/1.5 ML NDC# 72126-007-03 PREFILLED SYRINGE									
Primary Diagnosis: <input type="checkbox"/> Hereditary Transthyretin Amyloidosis (hATTR) <input checked="" type="checkbox"/> Other Diagnosis/Code _____									
<input type="checkbox"/> NKDA Allergies _____									
Concurrent Medications _____									
<input type="checkbox"/> Nurse Injection Training: Authorize RN visit to provide education related to therapy, disease state, administration and dosing, and titration per prescriber order									
Inject 284 mg/1.5 mL subcutaneously <input type="checkbox"/> Once weekly <input type="checkbox"/> Other Quantity: _____ (Maximum 30 day supply)									
IMPORTANT: TEGSEDI Rems Patient Attestation form required every 90 days to continue therapy. Refills _____									
Prescriber Signature (Dispense as Written) X _____ Date _____									
Prescriber Signature (Substitution Allowed) X _____ Date _____									
Supervising Physician Signature (where required) X _____ Date _____									